| HOME >> BIOLOGY >> TECHNOLOGY |
Dyadic makes financial disclosures through the OTC Disclosure and News Service which offers free information on the OTC Markets website (www.otcmarkets.com) concerning companies traded on the OTC Markets. Investors can access and download Dyadic's financial reports and other announcements that Dyadic makes through the OTC Markets website. Dyadic will also continue providing updates through regular press releases as appropriate.
Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31, 20102009Revenue:Product Related Revenue, Net
$
7,389,793
$
6,800,071License Fee Revenue37,25010,300,000Research and Development Revenue1,010,5594,321,258Total Revenue8,437,60221,421,329Cost of Goods Sold6,497,9356,292,411Gross Profit1,939,66715,128,918Expenses:General and Administrative5,157,7554,334,190Sales and Marketing 988,453958,143Research and Development 1,240,5101,211,035Foreign Currency Exchange Losses, Net148,42356,455Total Expenses7,535,1416,559,823Income (Loss) from Operations(5,595,474)8,569,095Other Income (Expense) Interest Income61,573141,811Interest Expense(248,319)(219,892)Loss on Stockholder Litigation-(3,250,000)Gain on Reduct
'/>"/>
| SOURCE Dyadic International, Inc. Copyright©2010 PR Newswire. All rights reserved |